Metasztatikus ovariumcarcinoma kemoterápiás kezelése nyolc éven át

作者: Dorottya Katalin Horváth , Judit Kósa , Ildikó Futó , András Telekes

DOI: 10.1556/650.2016.30565

关键词:

摘要: The authors present the history of a 48-year-old woman, who developed pleural effusion, abdominal pain and ascites due to an advanced ovarian cancer. She underwent hysterectomy bilateral adnexectomy in 2006, histology revealed FIGO IIIB papillary adenocarcinoma. After surgery patient recieved standard, 6 cycle taxol-carboplatin therapy. Taxol-carboplatin therapy was reinitiated because retroperitoneal lymph node metastases 2008, but soon had be changed progression. Thereafter different types chemo- biological including off-label FOLFOX-4 treatment at seventh line. Significant regression response confirmed with progression free survival about 9 months. general condition satisfying during whole chemotherapy, side effects were tolerable. overall 98 This case is good example for success individualized, long term chemotherapy even if tumor diagnosed stage as it happened this case. Orv. Hetil., 2016, 157(44), 1769-1773.

参考文章(12)
Ana Fernández Montes, Epidemiology and Etiology of Ovarian Cancer InTech. ,(2012) , 10.5772/27679
G. Scambia, Benedetti Panici, G. Baiocchi, L. Perrone, S. Greggi, P. Di Roberto, S. Mancuso, CA 15-3 serum levels in ovarian cancer. Oncology. ,vol. 45, pp. 263- 267 ,(1988) , 10.1159/000226575
Bradley J. Monk, David C. Choi, Gordon Pugmire, Robert A. Burger, Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecologic Oncology. ,vol. 96, pp. 902- 905 ,(2005) , 10.1016/J.YGYNO.2004.12.001
Hee Jun Lee, Hee Seung Kim, Noh Hyun Park, Hyun Hoon Chung, Jae Weon Kim, Yong Sang Song, Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer Cancer Research and Treatment. ,vol. 45, pp. 40- 47 ,(2013) , 10.4143/CRT.2013.45.1.40
LR Sharma, A Subedi, K Shah, Anaphylaxis to pegylated liposomal Doxorubicin: a case report. West Indian Medical Journal. ,vol. 63, pp. 376- 377 ,(2014) , 10.7727/WIMJ.2013.270
M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, J L Lewis, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of Clinical Oncology. ,vol. 9, pp. 389- 393 ,(1991) , 10.1200/JCO.1991.9.3.389
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang, Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer The New England Journal of Medicine. ,vol. 365, pp. 2473- 2483 ,(2011) , 10.1056/NEJMOA1104390
I Ralph Edwards, Jeffrey K Aronson, Adverse drug reactions: definitions, diagnosis, and management. The Lancet. ,vol. 356, pp. 1255- 1259 ,(2000) , 10.1016/S0140-6736(00)02799-9
APM HEINTZ, F ODICINO, P MAISONNEUVE, MA QUINN, JL BENEDET, WT CREASMAN, HYS NGAN, S PECORELLI, U BELLER, Carcinoma of the ovary. International Journal of Gynecology & Obstetrics. ,vol. 95, pp. 135- 166 ,(2003) , 10.1016/S0020-7292(06)60033-7
Mansoor Raza Mirza, Philippe Follana, David Bollag, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Deolinda Pereira, Pauline Wimberger, Ana Oaknin, Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial Journal of Clinical Oncology. ,vol. 32, pp. 1302- 1308 ,(2014) , 10.1200/JCO.2013.51.4489